Point-of-Care Molecular Diagnostics Market - Databook 2025 to 2034

The global point-of-care molecular diagnostics market size accounted for USD 8,670 million in 2024 and is predicted to touch around USD 12,710 million by 2034, growing at a CAGR of 3.9% from 2025 to 2034.

Point-of-Care Molecular Diagnostics Market Report Highlights

• By region, North America dominated the point-of-care molecular diagnostics market in 2024.
• By region, Asia Pacific is anticipated to grow fastest during the forecast period.
• By application, the infectious disease segment dominated the point-of-care molecular diagnostics market in 2024 and accounted for the highest revenue share.
• By application, the oncology segment is anticipated to grow fastest during the forecast period.
• By technology, the PCR-based segment held the largest market share in 2024 for the point-of-care molecular diagnostics market.
• By technology, the genetic-sequencing-based segment is expected to grow at the fastest CAGR during the forecast period.
• By location, the over-the-counter (OTC) segment dominated the point-of-care molecular diagnostics market in 2024.
• By location, the point of care (POC) segment is expected to grow fastest during the forecast period.
• By end-use, the decentralized labs end-use segment dominated the point-of-care molecular diagnostics market in 2024 with the largest revenue share.
• By end-use, the home care segment is expected to grow fastest during the forecast period.

Industry Valuation and Growth Rate Projection

The point-of-care molecular diagnostics market refers to the production, distribution, and application of point-of-care molecular diagnostics in which point-of-care testing is a diagnostic test performed outside of centralized microbiology and at or near the site of patient care. Molecular POCT should be rapid, sensitive, and specific to optimize TAT and accuracy per the REASSURED criteria. Point-of-care molecular diagnostic systems afford providers the ability to generate laboratory-quality results without the need for confirmatory testing of negative specimens.

Point-of-care diagnostic tests can be used as the initial test for sick or critical cases, providing a rapid initial diagnosis and allowing prompt, early, and proper management due to their shorter turnaround time. Mild and moderate cases requiring stabilizing and home treatment can depend solely on point-of-care tests for proper management. Molecular diagnostic tests are critical in determining treatment course and duration. These tests help physicians identify patients who are unlikely to respond to therapy in the long term and justify the discontinuation of therapy. Molecular diagnostics are used to identify infectious diseases like tuberculosis, chlamydia, and influenza virus or specific strains like SARS-CoV-2 or H1N1 virus.

Increasing demand for preventive medicines is driving the growth of the point-of-care molecular diagnostics market. Getting preventive medicine care reduces the risk of diseases, disabilities, and death. Preventive medicine refers to a medical specialty that focuses on protecting, promoting, and maintaining health and well-being, as well as preventing disability, disease, and death through three levels of promotion such as primary, secondary, and tertiary. The principles of preventive medicine include recognizing that health is influenced by biological, behavioral, environmental, and social factors. The focus is placed on promptly identifying and intervening, using evidence-based practices to identify risk factors and implement targeted strategies.

Preventive medicine is the application of healthcare measures to prevent diseases. Disease and disability are affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices and are dynamic processes that begin before individuals realize they are affected. Preventive medicine is the practice of promoting preventive healthcare to enhance patient well-being. Preventive medicine physicians provide advice, suggestions, and recommendations to help patients maintain or enhance their health and wellness.

Advancement in healthcare infrastructure driving the growth of the point-of-care molecular diagnostics market. A developed healthcare infrastructure also guarantees a country of strong and healthy manpower for the production of goods and services. Healthcare infrastructure includes advanced machines, nurses, specialist doctors, and other paramedical professionals and developed pharmaceutical industries. Healthcare infrastructure advancements improve patient care by providing healthcare professionals with better tools for diagnosis and treatment. Infrastructure powers businesses and connects workers to their jobs and citizens to opportunities for healthcare and education. It creates opportunities within communities, and an economy needs reliable infrastructure to connect supply chains and move goods and services. Infrastructure can also reduce the cost of delivered goods, facilitate the physical mobility of people and products, remove productivity constraints, and increase competitiveness.

The growing incidence of infectious diseases and cancer is driving the growth of the point-of-care molecular diagnostics market. In the context of infectious disease testing, molecular diagnostics are used to detect, identify, and characterize microscopic invaders, like bacteria and viruses, in our body. This method also tells us more about their features, like their strain type, drug resistance, and transmission patterns. Molecular diagnostics can also be used to help diagnose cancers. They can help differentiate cancer from benign tumors and can further help identify the type of tissue in which the cancer originated. Point of care is an initiative to evaluate the dissemination of state-of-the-art cancer therapy and diagnostics into community oncology practice and identify factors associated with cancer care.

• According to Volza’s Global Import Data, the World imported 437 shipments of Molecular Devices from March 2023 to February 2024. These imports were supplied by 70 exporters to 76 Global buyers, marking a growth rate of 66% compared to the preceding twelve months